Online inquiry

IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4557MR)

This product GTTS-WQ4557MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CXCR4 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001008540.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7852
UniProt ID P61073
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4557MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4677MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ7851MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ496MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ9560MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ12388MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ14025MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ8663MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ5350MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW